[Secondary hyperparathyroidism--treatment review]

Area of Science:

• Nephrology
• Endocrinology
• Biochemistry

Background:

• Secondary hyperparathyroidism is a frequent complication of chronic kidney disease (CKD).
• It is characterized by elevated parathormone (PTH) due to phosphate retention, low calcitriol (1,25(OH)2D), and high fibroblast growth factor 23 (FGF 23).
• Later stages may involve decreased free ionized calcium levels.

Purpose of the Study:

• To outline the management strategies for secondary hyperparathyroidism in CKD.
• To detail the biochemical drivers of the disorder.
• To present therapeutic options based on CKD stage and biochemical profile.

Main Methods:

• Review of current management guidelines for secondary hyperparparathyroidism in CKD.
• Discussion of pharmacological interventions including phosphate binders, calcitriol analogs, and calcimimetics.
• Consideration of surgical intervention (parathyroidectomy) when medical management fails.

Main Results:

• Initial management focuses on dietary phosphate restriction and phosphate binders.
• Calcitriol (1,25(OH)2D) or its analogs (alfacalcidol, paricalcitol) are used to manage vitamin D deficiency.
• Calcimimetics, alone or in combination with vitamin D compounds, are employed to reach therapeutic targets.

Conclusions:

• Treatment choice for secondary hyperparathyroidism is tailored to CKD stage and specific biochemical abnormalities.
• A stepwise approach involving dietary modifications, medications, and potentially surgery is effective.
• Achieving therapeutic goals often requires a combination of treatments.